Desmopressin Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: The Desmopressin Supply Landscape in 2026

Desmopressin Acetate (DDAVP, Stimate, Nocdurna, Noctiva) has been subject to intermittent supply disruptions since 2023, with particular impact on intranasal formulations. For prescribers across endocrinology, nephrology, hematology, urology, and pediatrics, understanding the current availability picture is essential for maintaining patient continuity of care.

This briefing provides a clinical overview of the shortage timeline, affected formulations, prescribing implications, and tools to help your patients maintain access to Desmopressin.

Shortage Timeline

The Desmopressin supply disruption has evolved through several phases:

• 2023: DDAVP nasal spray shortage triggered FDA-registered 503B compounding pharmacies (including STAQ Pharma in Denver, CO) to produce Desmopressin nasal spray. Product successfully passed 75-day stability testing, with pricing around $300 per vial. The Foundation for Women and Girls with Blood Disorders and the National Hemophilia Foundation were actively involved in coordinating alternative supply.
• Early 2025: Desmopressin 10 mcg/dose nasal spray was reported out of stock across multiple markets. The UK's MHRA issued a Medicine Supply Notification. Anticipated resupply was September 2025. Oral tablets, sublingual tablets, and DDAVP Melt oral lyophilisates (60, 120, and 240 mcg) remained available during this period.
• Late 2025–2026: Partial resupply of nasal formulations occurred, but availability remains inconsistent across regions. Generic oral tablets continue to maintain the most stable supply. Some facilities have reported periodic issues with injectable Desmopressin (4 mcg/mL) as well.

Prescribing Implications

The shortage creates several clinical challenges for prescribers:

Formulation Switching Requires Dose Adjustment

Bioavailability differs substantially across Desmopressin formulations. When transitioning patients between forms, dose recalculation is essential:

• IV/SC to intranasal: Administer approximately 10x the IV dose, rounding down to the nearest 10 mcg
• Oral tablets to intranasal: Individual dose titration is required; intranasal bioavailability (~3-5%) differs from oral (~0.1-0.16%)
• Sublingual (Nocdurna) to oral tablets: Nocdurna 27.7 mcg ≈ 0.1 mg oral; Nocdurna 55.3 mcg ≈ 0.2 mg oral (approximate, requires titration)

Monitor patients closely during any formulation switch, with particular attention to serum sodium levels and urine osmolality.

Hyponatremia Risk During Transitions

Desmopressin carries a boxed warning for hyponatremia. Risk is elevated during formulation switches when dose adjustments may be imprecise. Key monitoring considerations:

• Check serum sodium before switching formulations
• Recheck sodium within 7 days of the switch
• Reinforce fluid restriction counseling with every formulation change
• Elderly patients (≥65) and patients on SSRIs, NSAIDs, or carbamazepine are at highest risk

Bleeding Disorder Patients Require Special Attention

Patients with mild Hemophilia A or Von Willebrand Disease Type 1 who use Stimate (150 mcg/spray) for bleeding prophylaxis before procedures face unique challenges. Stimate cannot be directly substituted with standard DDAVP nasal spray (10 mcg/spray) — the concentrations differ by a factor of 15. When Stimate is unavailable:

• Consider IV Desmopressin (0.3 mcg/kg) administered in a clinical setting
• Consult hematology for factor VIII concentrate alternatives (Advate, Kogenate, Eloctate)
• Tranexamic acid can be used as adjunctive therapy for minor procedures

Current Availability Picture

FormulationStatus (Early 2026)NotesGeneric oral tablets (0.1, 0.2 mg)Generally availableMost stable supply; multiple generic manufacturersDDAVP nasal spray (10 mcg)Intermittent shortagesBranded supply inconsistent; generic nasal spray variably availableStimate nasal spray (150 mcg)Periodic shortagesLimited manufacturers; consult hematology for alternativesNocdurna sublingual (27.7, 55.3 mcg)Generally availableMay require prior authorizationNoctiva nasal sprayLimited availabilityDistribution challenges ongoingInjection (4 mcg/mL)VariableHospital supply generally more stable

Cost and Access Considerations

Cost barriers compound supply issues for many patients:

• Generic oral tablets: $20-$55/month with discount coupons — affordable for most patients
• Branded nasal sprays (DDAVP): $200-$400 without insurance — may trigger cost-related non-adherence
• Stimate: $3,000-$5,000 — specialty pricing; most patients require insurance or patient assistance
• Nocdurna: $400-$500 without insurance — Ferring offers co-pay savings programs

Insurance coverage: Generic Desmopressin tablets are covered by approximately 70% of plans with typical co-pays of $10-$30. Brand formulations often require prior authorization or step therapy (trial of generic tablets first).

Patient assistance: Ferring Pharmaceuticals offers patient assistance and co-pay card programs. NeedyMeds and RxAssist maintain directories of additional programs. Direct patients to our patient savings guide for Desmopressin.

Tools and Resources for Your Practice

Medfinder for Providers allows prescribers and clinical staff to search real-time pharmacy inventory for Desmopressin across formulations. This can help your team:

• Direct patients to pharmacies with confirmed stock
• Reduce failed fill rates and medication interruptions
• Identify which formulations are available in your area before writing prescriptions

Additional resources:

• FDA Drug Shortage Database: Official shortage listings and expected resolution dates
• ASHP Drug Shortage Resource Center: Clinical alternatives and management strategies
• Compounding pharmacy networks: 503B outsourcing facilities may produce Desmopressin nasal spray during commercial product shortages

Looking Ahead

Several factors may improve the Desmopressin supply situation:

• Additional generic manufacturers entering the intranasal market
• Ongoing production scaling by Ferring Pharmaceuticals
• Established compounding pharmacy supply chains that can be reactivated during shortages

However, the fundamental vulnerability — concentrated manufacturing for a specialty peptide product — remains. Prescribers should maintain proactive contingency plans for their Desmopressin-dependent patients.

Final Thoughts

The Desmopressin shortage requires prescribers to stay informed, flexible, and communicative with patients. Proactive formulation switching, careful dose adjustment, sodium monitoring, and leveraging tools like Medfinder for Providers can help maintain continuity of care during this challenging supply period.

For a patient-facing version of this update, you can direct patients to our Desmopressin shortage update for patients. For workflow tips on helping patients navigate stock issues, see our provider's guide to helping patients find Desmopressin.